TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00359801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Description: Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Description: Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study: NCT04246827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Lifestyle Weight Management
Description: The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
Study: NCT03420586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
Study: NCT03353012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel Drug Implant
Description: Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel Drug Implant
Description: Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel Drug Implant
Description: Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Drug Implant
Description: Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
Study: NCT00824044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
Study: NCT00678119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Dendritic cell Immunotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: An approved drug for the treatment of RCC
Study: NCT00861146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling plus contingency management
Description: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral counseling plus contingency management
Description: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
Study: NCT02334007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH: Dalteparin
Description: Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
Study: NCT03593265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUNIX
Description: Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
Study: NCT03238404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAC group
Description: NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone group
Description: Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
Study: NCT03216863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Description: It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
Study: NCT01887574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnaires given to all patients to assess risk factors and quality of life
Study: NCT00496093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine, Polyvalent (23-valent)
Study: NCT00488163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
Study: NCT05462808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stainless steel crown
Description: Stainless steel crown
Study: NCT00944463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+simvastatin
Description: Gemcitabine and simvastatin
Study: NCT02395718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QDU
Description: Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIM
Description: Treatment at a ward at the DIM. Traditional inward hospitalisation
Study: NCT03388619

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate bed with integrated boost
Description: Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate bed irradiation only
Description: Radiation will be delivered to the prostate bed only.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body Bone Scan
Description: At screening, if required by clinician.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body Bone Scan
Description: At screening, if required by clinician.
Study: NCT00944463

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine+Placebo
Description: Gemcitabine plus Placebo
Study: NCT01898273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-124-CLR1404
Description: single-dose, intravenous
Study: NCT01476566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
Study: NCT01335035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Study: NCT01068262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Oral Placebo tablet administered once weekly for 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Oral Placebo tablet administered once weekly for 4 consecutive weeks
Study: NCT00612508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogen (ethinyl estradiol and desogestrel)
Description: 1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing (ethinyl estradiol and etonogestrel)
Description: Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
Study: NCT03388619

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET Imaging
Description: At screening, if required by clinician.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET Imaging
Description: At screening, if required by clinician.
Study: NCT00627536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
Study: NCT03388619

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: mpMRI of the prostate bed at screening and 6 month follow up.
Study: NCT02997111

Intervention type: DEVICE
Group type: OTHER
Intervention: PFA-100
Description: The PFA-100 will be used to assess platelet function before and after energy drink consumption.
Study: NCT03874208

Intervention type: OTHER
Group type: OTHER
Intervention: MRI sequence
Description: An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI exam
Study: NCT04541836

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-PMPBB3
Description: single intravenous injection 5mCi 18F-PMPBB3 per scan

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-PMPBB3
Description: single intravenous injection 5mCi 18F-PMPBB3 per scan
Study: NCT01365104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desferrioxamine
Description: intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
Study: NCT00627536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
Study: NCT00998933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62%
Description: 5 grams applied topically to upper arms/shoulder and abdomen on Day 1
Study: NCT02781038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching intervention
Description: Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
Study: NCT00627536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to avotermin dosage strength

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to avotermin dosage strength

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to avotermin dosage strength

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to avotermin dosage strength
Study: NCT04552548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regional nerve block
Description: Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regional nerve block
Description: Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
Study: NCT02584387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D Video Virtual Reality Exposure Therapy
Description: The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
Study: NCT03189654

Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
Study: NCT03980717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldbal Detachable Balloon and delivery microcatheter
Description: Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
Study: NCT04710914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged sedation with isoflurane
Description: Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged sedation with midazolam
Description: Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam
Study: NCT02916459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 21G EBUS-TBNA needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible 19G EBUS-TBNA needle
Study: NCT01439126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine hydrochloride
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
Study: NCT03720600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAB Intervention
Description: The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MAB Intervention
Description: The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
Study: NCT03039894

Intervention type: OTHER
Intervention: Gradebook Game
Description: Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
Study: NCT03388619

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: mpMRI of the prostate bed at screening and 6 month follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
Study: NCT02203656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home exercise
Description: In-home exercise program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone injection
Study: NCT03033056

Intervention type: BEHAVIORAL
Intervention: Test of fear conditioning
Description: Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
Study: NCT03388619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
Study: NCT01498614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect School and Basal body awareness
Description: Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
Study: NCT02168985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TFH program
Description: The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
Study: NCT04400578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid 85% (TCA)
Description: Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
Study: NCT00566865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for gemfibrozil
Description: mitiglinide + placebo for gemfibrozil 600 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Description: Mitiglinide + 600 mg gemfibrozil bid
Study: NCT02968914

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
Study: NCT03776773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pollution exposure
Description: Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
Study: NCT02526888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Oral capsule (25 mg) as single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Oral capsule (25 mg) as single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7